NASDAQ:ICPT
Delisted
Intercept Pharmaceuticals Stock News
$19.00
+0 (+0%)
At Close: Feb 06, 2024
Intercept Pharmaceuticals (NASDAQ:ICPT) Lowered to “Hold” at Credit Suisse Group
04:00am, Tuesday, 30'th Jun 2020
Credit Suisse Group cut shares of Intercept Pharmaceuticals (NASDAQ:ICPT) to a hold rating in a research note issued to investors on Monday, TipRanks reports. The firm currently has $59.00 price targe
Alexion's European Approval And Other News: The Good, Bad And Ugly Of Biopharma
03:45am, Tuesday, 30'th Jun 2020
Alexion's Ultomiris is approved in Europe. Intercept suffers a setback. Ascendis applies for label expansion of TransCon.
LOS ANGELES--(BUSINESS WIRE)--$ICPT #fraud--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on
A Peek Into The Markets: US Stock Futures Down Following Monday's Rally
12:00am, Tuesday, 30'th Jun 2020
Pre-open movers
U.S. stock futures traded lower in early pre-market trade, after posting strong gains in the earlier session. The S&P Corelogic Case-Shiller home price index...
Aquí está la razón por la que el precio de las acciones de Intercept se cayó hoy en un 40%. | Invezz
10:25pm, Monday, 29'th Jun 2020
Las acciones de Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) se cayeron más del 40% después de que la Administración de Drogas y Alimentos de EE.UU. (FDA) se negó a aprobar la terapia de la empre
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Intercept Pharmaceuticals, Inc. on Behalf of Investors
Intercept Drops as FDA Refuses Speedy Approval of Liver Drug - BNN Bloomberg
08:20pm, Monday, 29'th Jun 2020
Intercept Pharmaceuticals Inc. shares plummeted Monday as U.S. regulators dashed hopes for an accelerated approval of what investors thought would be the first medicine to treat tens of millions of pe
Intercept Shares Tumble on NASH Disappointment
08:05pm, Monday, 29'th Jun 2020
Questions about drugs aimed at treating the liver disease have been bubbling up for months.
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)
08:00pm, Monday, 29'th Jun 2020
The Law Offices of Frank R. Cruz announces an investigation on behalf of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) investors concerning the Company and its officers
Oil futures climb, with U.S. prices up more than 3%
06:40pm, Monday, 29'th Jun 2020
Oil futures climbed on Friday, with U.S. prices up by more than 3%, finding support from some recovery in energy demand, even as that recovery is threatened...
Xconomy: FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data
06:08pm, Monday, 29'th Jun 2020
The FDA has rejected an Intercept Pharmaceuticals drug developed to treat the fatty liver disorder nonalcoholic steatohepatitis, more commonly referred to
FDA turns down Intercept’s long-anticipated NASH drug
05:06pm, Monday, 29'th Jun 2020
The FDA has requested additional data from the company's clinical trial. Intercept's CEO expressed disappointment at the decision, saying the agency had not communicated that the drug, obeticholic aci
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors
Here’s why Intercept stock price collapsed 40% today | Invezz
03:37pm, Monday, 29'th Jun 2020
Shares of Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) plunged over 40% after the U.S. Food and Drug Administration (FDA) declined to approve the firm’s therapy for liver disease. As a result, Inte
NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intercept Pharmaceuticals, Inc. ("Intercept" or "the ...
